. 2020 Nov 24;19:198. doi: 10.1186/s12933-020-01176-4

Table 5.

Effects of metformin on ventricular arrhythmias: reports from clinical trials

Model	Type of study/No. of patients/FU	Metformin (dose/duration)	Key results and major findings	Interpretation	References
DM patients with CAD monitored via 24-h Holter monitor (mean age 55)	Randomized crossover design/19 patients/2 weeks	Metformin 500 mg BID for 2 weeks	- <-> PVC/NSVT per minute of ischemia	Metformin did not reduce PVC/NSVT in diabetic CAD patients	[94]
Hospitalized DM patients with AMI (mean age 56)	Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI	Various doses	- <-> 28-days VT/VF incidence	Metformin alone or in combination with other anti-DM drugs was not associated with decreased 28-day post AMI VT/VF incidence	[56]

Model

Type of study/No. of patients/FU

Metformin (dose/duration)

Key results and major findings

Interpretation

References

DM patients with CAD monitored via 24-h Holter monitor

(mean age 55)

Randomized crossover design/19 patients/2 weeks

Metformin 500 mg BID for 2 weeks

- <-> PVC/NSVT per minute of ischemia

Metformin did not reduce PVC/NSVT in diabetic CAD patients

[94]

Hospitalized DM patients with AMI

(mean age 56)

Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI

Various doses

- <-> 28-days VT/VF incidence

Metformin alone or in combination with other anti-DM drugs was not associated with decreased 28-day post AMI VT/VF incidence

[56]

AMI acute myocardial infarction, CAD coronary artery disease, DM diabetes mellitus, PVC/NSVT premature ventricular contraction/non-sustained ventricular tachycardia, VT/VF ventricular tachycardia/ventricular fibrillation